Literature DB >> 15497158

Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.

Jessica Y Leung1, Andrew X Zhu, Fredric D Gordon, Daniel S Pratt, Abigail Mithoefer, Kathryn Garrigan, Adam Terella, Martin Hertl, A Benedict Cosimi, Raymond T Chung.   

Abstract

The incidence of hepatocellular carcinoma (HCC), a frequent and incurable complication of cirrhosis, continues to rise. Orthotopic liver transplantation (OLT) has been proposed as a treatment for unresectable, intrahepatic HCC limited in extent to the Milan criteria adopted by the United Network of Organ Sharing (UNOS) in 1998. More recently, somewhat less restrictive University of California, San Francisco (UCSF)10, criteria were proposed. To examine the long-term outcomes of OLT for HCC patients and to assess the UNOS policy of assigning weighted allocation points to patients with HCC, we retrospectively analyzed 144 patients (113 after 1998) with HCC who underwent OLT over an 11-year period at 3 institutions from UNOS Region 1. We compared their outcomes with 525 patients (272 after 1998) who underwent OLT for nonmalignant liver disease. The 1- and 5-year survival rates were 80.3% and 46.7%, respectively, for patients with HCC and 81.5% and 70.6%, respectively, for patients without HCC (P = .020). However, there was no difference in survival between HCC and non-HCC patients after implementation of disease-specific allocation for HCC in 1998. A higher proportion of the HCC cohort was older and male and had chronic HCV infection and alcoholic liver disease. In univariate analysis, having alpha-fetoprotein (AFP) levels of 10 ng/mL or less and meeting clinical and pathologic UCSF criteria were each significant predictors of improved survival (P = .005, P = .02, and P = .03, respectively). AFP greater than 10 ng/mL and exceeding pathologic UCSF criteria were also significant predictors of recurrence (P = .003 and P = .02, respectively). In conclusion, taken together, our data suggest that OLT is an acceptable option for patients with early HCC and that UCSF criteria predict outcome better than Milan or UNOS criteria. Regardless of which criteria are adopted to define eligibility, strict adherence to the criteria is important to achieve acceptable outcomes.

Entities:  

Mesh:

Year:  2004        PMID: 15497158     DOI: 10.1002/lt.20311

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  24 in total

1.  Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach?

Authors:  Georgios C Sotiropoulos; Nina Drühe; George Sgourakis; Ernesto P Molmenti; Susanne Beckebaum; Hideo A Baba; Gerald Antoch; Philip Hilgard; Arnold Radtke; Fuat H Saner; Silvio Nadalin; Andreas Paul; Massimo Malagó; Christoph E Broelsch; Hauke Lang
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

2.  KiSS-1 overexpression as an independent prognostic marker in hepatocellular carcinoma: an immunohistochemical study.

Authors:  Katharina Schmid; Xiaowei Wang; Andrea Haitel; Wolfang Sieghart; Markus Peck-Radosavljevic; Martin Bodingbauer; Susanne Rasoul-Rockenschaub; Fritz Wrba
Journal:  Virchows Arch       Date:  2007-02       Impact factor: 4.064

Review 3.  HCC: current surgical treatment concepts.

Authors:  F Cauchy; D Fuks; J Belghiti
Journal:  Langenbecks Arch Surg       Date:  2012-06       Impact factor: 3.445

Review 4.  Recent advances in the surgical treatment of hepatocellular carcinoma.

Authors:  Zenichi Morise; Norihiko Kawabe; Hirokazu Tomishige; Hidetoshi Nagata; Jin Kawase; Satoshi Arakawa; Rie Yoshida; Masashi Isetani
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

Review 5.  Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies.

Authors:  Yee Lee Cheah; Pierce K H Chow
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

6.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

Review 7.  The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.

Authors:  Guido Beldi; Keiichi Enjyoji; Yan Wu; Lindsay Miller; Yara Banz; Xiaofeng Sun; Simon C Robson
Journal:  Front Biosci       Date:  2008-01-01

8.  Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection (#JGSU-D-07-00462).

Authors:  Kiyoshi Hasegawa; Hiroshi Imamura; Masayoshi Ijichi; Yutaka Matsuyama; Keiji Sano; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  J Gastrointest Surg       Date:  2008-01-18       Impact factor: 3.452

9.  Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma.

Authors:  Matteo Cescon; Matteo Ravaioli; Gian Luca Grazi; Giorgio Ercolani; Alessandro Cucchetti; Valentina Bertuzzo; Gaetano Vetrone; Massimo Del Gaudio; Marco Vivarelli; Antonietta D'Errico-Grigioni; Alessandro Dazzi; Paolo Di Gioia; Augusto Lauro; Antonio Daniele Pinna
Journal:  J Transplant       Date:  2010-08-25

Review 10.  Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies.

Authors:  Long Sun; Hua Wu; Yong-Song Guan
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.